Postmenopausal Breast Cancer

Abstract

In summarising current drug treatment strategies for postmenopausal women with breast cancer, it is essential to emphasise that we are dealing with a group of diseases that are treatable, and that appropriate treatment decisions will give longer disease-free intervals for patients with early breast cancer, and better control with better survival for patients with advanced (i.e. locally advanced and/or metastatic) disease. Women greater than 65 years of age have a predictably better response to hormone treatment versus women less than 65 years of age. Hormone treatment may, therefore, be considered as primary treatment or as adjuvant treatment after limited surgery. Hormone treatment is also the treatment of first choice for elderly patients with advanced disease. For middle-aged women (45 to 65 years of age), various patient factors are important in predicting the value of treatment. Estrogen receptor (ER) status is prognostic of survival irrespective of treatment. Patients with ER-positive disease have a better prognosis than those with ER-negative disease, both in the adjuvant setting and in the face of metastatic disease. This is because ER-positive tumours tend to grow slower. The availability of the serotonin type 3 (5-hydroxytryptamine;5-HT3) antagonists, which effectively control nausea and vomiting in most patients, make chemotherapy combinations more acceptable, and combination chemotherapy can more readily be considered as first treatment option both as adjuvant treatment and for treatment of advanced disease. For patients with organ metastases there is no doubt that combined chemotherapy treatment is indicated.

Granisetron, ein neues und potentes Antiemetikum zur Behandlung der zytostatikainduzierten Emesis gynäkologischer Malignome

“…3 zu entne hmen ist , bei un ser en Patientinnen hauptsä chlich während des dritten und vier ten Chem otherapi ezyklus einste llte. Von den 77 Patient innen ha tten 26 % den "worst day " währe nd des dritten Chem otherapiekurses, 25 % wä h rend des vierte n Kurses, 18 % wä h rend des zwe iten Kurses, 14 % während In uns er er Studie konnten wir die hohe Wirksa mkeit von Gra nisetron, wie sie schon in den Phase I Studien von Falks on et al (10), Bermud ez et al (21. Cass idy et al (4), San ger u. Nelson (24) und Carmichael et al 3beschrieben wurden , nachvollziehe n. Nausea und Erb rec he n kon nten durch die prophylakti sche Gab e von Gran isetron effektiv bekäm pft werden .…”